193 related articles for article (PubMed ID: 19385712)
1. Population pharmacokinetics of orally administered duloxetine in patients: implications for dosing recommendation.
Lobo ED; Quinlan T; O'Brien L; Knadler MP; Heathman M
Clin Pharmacokinet; 2009; 48(3):189-97. PubMed ID: 19385712
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of orally administered duloxetine in children and adolescents with major depressive disorder.
Lobo ED; Quinlan T; Prakash A
Clin Pharmacokinet; 2014 Aug; 53(8):731-40. PubMed ID: 24989060
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and tolerability of duloxetine following oral administration to healthy Chinese subjects.
Tianmei S; Knadler MP; Lim MT; Yeo KP; Teng L; Liang S; Pan AX; Lobo ED
Clin Pharmacokinet; 2007; 46(9):767-75. PubMed ID: 17713974
[TBL] [Abstract][Full Text] [Related]
4. Effect of age on the pharmacokinetics of duloxetine in women.
Skinner MH; Kuan HY; Skerjanec A; Seger ME; Heathman M; O'Brien L; Reddy S; Knadler MP
Br J Clin Pharmacol; 2004 Jan; 57(1):54-61. PubMed ID: 14678340
[TBL] [Abstract][Full Text] [Related]
5. Duloxetine: clinical pharmacokinetics and drug interactions.
Knadler MP; Lobo E; Chappell J; Bergstrom R
Clin Pharmacokinet; 2011 May; 50(5):281-94. PubMed ID: 21366359
[TBL] [Abstract][Full Text] [Related]
6. Effects of varying degrees of renal impairment on the pharmacokinetics of duloxetine: analysis of a single-dose phase I study and pooled steady-state data from phase II/III trials.
Lobo ED; Heathman M; Kuan HY; Reddy S; O'Brien L; Gonzales C; Skinner M; Knadler MP
Clin Pharmacokinet; 2010 May; 49(5):311-21. PubMed ID: 20384393
[TBL] [Abstract][Full Text] [Related]
7. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers.
Skinner MH; Kuan HY; Pan A; Sathirakul K; Knadler MP; Gonzales CR; Yeo KP; Reddy S; Lim M; Ayan-Oshodi M; Wise SD
Clin Pharmacol Ther; 2003 Mar; 73(3):170-7. PubMed ID: 12621382
[TBL] [Abstract][Full Text] [Related]
8. Duloxetine pharmacokinetics in cirrhotics compared with healthy subjects.
Suri A; Reddy S; Gonzales C; Knadler MP; Branch RA; Skinner MH
Int J Clin Pharmacol Ther; 2005 Feb; 43(2):78-84. PubMed ID: 15726876
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine.
Lobo ED; Bergstrom RF; Reddy S; Quinlan T; Chappell J; Hong Q; Ring B; Knadler MP
Clin Pharmacokinet; 2008; 47(3):191-202. PubMed ID: 18307373
[TBL] [Abstract][Full Text] [Related]
10. Oral olanzapine disposition in adolescents with schizophrenia or bipolar I disorder: a population pharmacokinetic model.
Lobo ED; Robertson-Plouch C; Quinlan T; Hong Q; Bergstrom RF
Paediatr Drugs; 2010 Jun; 12(3):201-11. PubMed ID: 20297865
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of duloxetine in breast milk and plasma of healthy postpartum women.
Lobo ED; Loghin C; Knadler MP; Quinlan T; Zhang L; Chappell J; Lucas R; Bergstrom RF
Clin Pharmacokinet; 2008; 47(2):103-9. PubMed ID: 18193916
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study.
Zhao RK; Cheng G; Tang J; Song J; Peng WX
Clin Ther; 2009 May; 31(5):1022-36. PubMed ID: 19539103
[TBL] [Abstract][Full Text] [Related]
13. A comparison of initial duloxetine dosing strategies in patients with major depressive disorder.
Whitmyer VG; Dunner DL; Kornstein SG; Meyers AL; Mallinckrodt CH; Wohlreich MM; Gonzales JS; Greist JH
J Clin Psychiatry; 2007 Dec; 68(12):1921-30. PubMed ID: 18162024
[TBL] [Abstract][Full Text] [Related]
14. Effects of duloxetine on the pharmacodynamics and pharmacokinetics of warfarin at steady state in healthy subjects.
Chappell J; He J; Knadler MP; Mitchell M; Lee D; Lobo E
J Clin Pharmacol; 2009 Dec; 49(12):1456-66. PubMed ID: 19793910
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor.
Sharma A; Goldberg MJ; Cerimele BJ
J Clin Pharmacol; 2000 Feb; 40(2):161-7. PubMed ID: 10664922
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgery.
Mueck W; Eriksson BI; Bauer KA; Borris L; Dahl OE; Fisher WD; Gent M; Haas S; Huisman MV; Kakkar AK; Kälebo P; Kwong LM; Misselwitz F; Turpie AG
Clin Pharmacokinet; 2008; 47(3):203-16. PubMed ID: 18307374
[TBL] [Abstract][Full Text] [Related]
17. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain.
Wernicke JF; Pritchett YL; D'Souza DN; Waninger A; Tran P; Iyengar S; Raskin J
Neurology; 2006 Oct; 67(8):1411-20. PubMed ID: 17060567
[TBL] [Abstract][Full Text] [Related]
18. Duloxetine for the management of diabetic peripheral neuropathic pain: response profile.
Pritchett YL; McCarberg BH; Watkin JG; Robinson MJ
Pain Med; 2007; 8(5):397-409. PubMed ID: 17661853
[TBL] [Abstract][Full Text] [Related]
19. The effects of supratherapeutic doses of duloxetine on blood pressure and pulse rate.
Derby MA; Zhang L; Chappell JC; Gonzales CR; Callaghan JT; Leibowitz M; Ereshefsky L; Hoelscher D; Leese PT; Mitchell MI
J Cardiovasc Pharmacol; 2007 Jun; 49(6):384-93. PubMed ID: 17577103
[TBL] [Abstract][Full Text] [Related]
20. Duloxetine: a review of its use in the treatment of generalized anxiety disorder.
Carter NJ; McCormack PL
CNS Drugs; 2009; 23(6):523-41. PubMed ID: 19480470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
